LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.11 -0.89

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.1

Max

1.12

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-31M 72M
Eelmine avamishind	2
Eelmine sulgemishind	1.11

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. veebr 2026, 23:21 UTC

Omandamised, ülevõtmised, äriostud

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15. veebr 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15. veebr 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15. veebr 2026, 23:06 UTC

Tulu

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15. veebr 2026, 23:04 UTC

Tulu

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15. veebr 2026, 23:04 UTC

Tulu

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15. veebr 2026, 23:01 UTC

Tulu

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15. veebr 2026, 23:01 UTC

Tulu

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15. veebr 2026, 22:52 UTC

Omandamised, ülevõtmised, äriostud

Qube Shareholders to Receive A$5.20/Share in Cash

15. veebr 2026, 22:52 UTC

Omandamised, ülevõtmised, äriostud

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO Tania Archibald Speaking on a Call With Media

15. veebr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15. veebr 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15. veebr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15. veebr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15. veebr 2026, 20:48 UTC

Tulu

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15. veebr 2026, 20:47 UTC

Tulu

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15. veebr 2026, 20:46 UTC

Tulu

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15. veebr 2026, 20:45 UTC

Tulu

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15. veebr 2026, 20:44 UTC

Tulu

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15. veebr 2026, 20:44 UTC

Tulu

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15. veebr 2026, 20:43 UTC

Tulu

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15. veebr 2026, 20:42 UTC

Tulu

BlueScope Net Debt A$2.2 Million at Dec. 31

15. veebr 2026, 20:42 UTC

Tulu

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15. veebr 2026, 20:41 UTC

Tulu

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15. veebr 2026, 20:40 UTC

Tulu

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15. veebr 2026, 20:40 UTC

Tulu

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15. veebr 2026, 20:39 UTC

Tulu

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnangu Konsensus

By TipRanks

Müü

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.